Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Services›Services›Commercial Services & Supplies

SUPHA PHARMACHEM LIMITED

Services › Commercial Services & Supplies
₹0.27
at close · 21 Sept 2026
▲ 0.01 (+3.85%)

Latest filings

  1. NCLAT interim order in Supha Pharmachem CIRP matter · Regulatory & Legal
  2. Trading window closed from July 1 till Q1 results declaration · Compliance
  3. Appointment of Resolution Professional in place of Interim Resolution Professional · Regulatory & Legal
  4. Disclosure to take note of decisions taken in 1st COC meeting held on 14.04.2026 · Regulatory & Legal
  5. This disclosure is to place on record List of Creditors as required to be placed under Reg 13(2)(c) of IBBI CIRP Regulations · Regulatory & Legal
  6. Update on CIRP Proceedings, Non-Cooperation by Directors (Power suspended) and Postponement of Board Meeting under Regulation 30 of SEBI (LODR) Regulation, 2015 · Regulatory & Legal
  7. Closure of Trading window · Compliance
  8. Intimation of receipt of Order from National Company Law Tribunal (NCLT) · Regulatory & Legal
  9. Submission of Form A - PUBLIC ANNOUNCEMENT · Compliance
  10. Intimation for Admission of Co. under CIRP and appointment of IRP · Regulatory & Legal
  11. Intimation of change in registered office of the company to office no. F81D, Express Zone Mall, A wing Next to Patel Vanika, W.E. Highway, Goregaon, (East), Mumbai - 400063, w.e.f. 17th .... · General
  12. Supha Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/03/2026 ,inter alia, to consider and approve To consider Un-Audited Financial .... · Results
  13. Supha Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/03/2026 ,inter alia, to consider and approve unaudited standalone and consolidated .... · Results
  14. Supha Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/02/2026 ,inter alia, to consider and approve unaudited standalone and consolidated .... · Results
  15. Rescheduling on 25/02/2026 · Results
  16. Demise of CS and Compliance Officer · Management Changes
  17. Supha Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve Un-Audited Financial Results/Statements .... · Results
  18. Submission of Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31.12.2025 · Compliance
  19. Intimation of closure of Trading Window · Compliance
  20. Company is pleased to informed that MCA has approved the change of name vide certificate of incorporation W.E.F. 15/12/2025 from REMEDIUM LIFECARE LTD. TO SUPHA PHARMACHEM LIMITED · Corporate Actions
  21. Submission of postal ballot results and scrutinizer report · Management Changes
  22. Submission of outcome of postal ballot · Board & Shareholder Meetings
  23. Newspaper Publication for unaudited financial results 30.09.2025 · Compliance
  24. Remedium Lifecare Delivers Strong Q2 Results with Profit Nearly Doubling to Rs.862.34 Lakh · Compliance
  25. Financial Results for Quarter and Half Year ended September 30, 2025 · Results
  26. Board Meeting Outcome for The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter and Half year Ended September 30, 2025 · Results
  27. Remedium Lifecare Strengthens Leadership for Next-Phase Growth · Compliance
  28. Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve Unaudited Standalone and .... · Results
  29. Newspapers publication for dispatch of postal ballot notice · Compliance
  30. Submission of postal ballot notice · Board & Shareholder Meetings
  31. Appointment · Management Changes
  32. the Board in ite metting approved 1. Appointed Mr. Rambhajan Vishwakarma . 2. Appointed Mr. Vignesh Laxman Gawde . 3. Approved the Postal Ballot notices 4. The Board has reconstituted .... · Management Changes
  33. Resignation of Mr. Mansoor Abdul Vahab · Management Changes
  34. Compliance certificate under Reg. 74(5) of SEBI (DP) 30.09.2025 · Compliance
  35. Resignation of Mr. Dipesh Vaidya Non- Executive Independent Director · Management Changes
  36. e-voting results of AGM and scrutinizer Report of AGM held on 24.09.2025 through VC/OAVM · Board & Shareholder Meetings
  37. Proceedings of 36th AGM held on 24.09.2025 through VC/OAVM · Board & Shareholder Meetings
  38. Intimation of closure of trading window · Compliance
  39. We wish to inform you that, the Board of Directors of the Company, at its meeting held today 22nd September, 2025 has inter- alia considered, approved and taken on record 1. Change of .... · Corporate Actions
  40. Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/09/2025 ,inter alia, to consider and approve Pursuant to Regulation 29 .... · Corporate Actions
  41. Newspaper ad for AGM notice Dispatch · Compliance
  42. submision of Annual Report 2024-25 · Board & Shareholder Meetings
  43. 36th Annual General Meeting of the company to be held on Wednesday, 24th September, 2025 at 11.00 a.m. through VC/OAVM · Board & Shareholder Meetings
  44. Submission of newspaper publication intimating members for holding ensuing AGM for 2024-25 through VC/OAVM · Compliance
  45. Remedium Lifecare Charts 4X Growth Path with Strategic Focus on 4-Point Strategy · Compliance
  46. Submission of Scrutinizer Report for postal Ballot process · Compliance
  47. Outcome of Postal ballot - Proceedings · Board & Shareholder Meetings
  48. Remedium Lifecare Kicks Off FY26 with ?464.88 Lakh PAT in Q1, Surpassing and Doubling FY25 Profit and Driving Expansion Plans · Compliance
  49. Results For The Quarter Ended June 30, 2025. · Results
  50. Board Meeting Outcome for The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended June 30, 2025 · Results
All filings ↓
Ask Nexa about SUPHA PHARMACHEM LIMITED

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Trades and distributes pharmaceutical chemicals, with operations routed through a Singapore subsidiary that drives nearly all of its consolidated revenue. On a consolidated basis, Q2 FY26 revenue from operations was Rs. 11,105.82 lakh and consolidated profit after tax was Rs. 862.34 lakh in the same quarter, while the standalone Indian entity reported only Rs. 857.79 lakh in revenue and a profit after tax of Rs. 20.12 lakh for H1 FY26, showing that the standalone Indian trading book has shrunk sharply. The company describes itself as expanding contract development and manufacturing (CDMO) capabilities through its overseas arm, Remlife Global PTE, which is the main contributor to consolidated revenue and profit. The Singapore subsidiary's delayed financial reporting has repeatedly held up the parent's consolidated results. On the cost side, FY25 employee cost was Rs. 0.76 crore (0.2% of revenue) and other operating expenses were Rs. 7.45 crore (1.8% of revenue), with a thin EBITDA margin of 2.4%. The company is currently under the Corporate Insolvency Resolution Process (CIRP) admitted by NCLT Mumbai on 17 March 2026 on a Section 9 petition by operational creditor Boston Ivy Healthcare Solutions over unpaid chemical supply invoices of Rs. 7.47 crore, with the Resolution Professional in charge and the prior board's powers suspended.

Operating scale
Consolidated Q2 FY26 revenue from operations
Rs. 11,105.82 lakhQ2 FY26
Consolidated Q2 FY26 profit after tax
Rs. 862.34 lakhQ2 FY26
Consolidated H1 FY26 profit after tax
Rs. 1,327.22 lakhH1 FY26
Total consolidated assets
Rs. 1,62,318.10 lakhAs of 30 September 2025
Standalone total assets
Rs. 1,52,931.68 lakhAs of 30 September 2025
Overseas subsidiary driving consolidated revenue
Remlife Global PTE (Singapore)
Who pays it
Pharmaceutical companies buying chemicals, with consolidated sales booked largely through the Singapore subsidiary
Biggest cost
Purchases of pharmaceutical chemicals (cost line not separately disclosed in the pack)
Kind of business
Trading and distribution-led pharma chemicals business, currently under CIRP with an overseas subsidiary accounting for most of consolidated revenue
Where it sits
Small BSE-listed entity in pharmaceutical chemicals trading and distribution, with the bulk of consolidated activity routed through a Singapore subsidiary and currently admitted to insolvency resolution
Market Cap
₹24 Cr
P / E (TTM)
—
EV / EBITDA
—
Div Yield
—
Growth
—·
Revenue 5y CAGR
PAT — · EBITDA —
Quality
22.0%▲
ROCE (5y median)
ROE 4.9% · margin 2.4%
Leverage
26.01·
Debt / Equity · high
Net debt ₹1,087 Cr
Moves on a normal day
2.78%·
Median daily move
Last 249 sessions · filing days run larger
Where it sits among 188 Trading & Distributors peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#15/164
P/B#11/146
ROCE#26/184
ROE#29/174
Debt / Equity#174/175
EBITDA margin#44/137

Scorecard

Measured from the filed financials, judged against its Trading & Distributors peers · as of FY25 — not investment advice

Strengths
Returns on capital 22.0%
#26 of 184 in Trading & Distributors on the latest reported figures
Concerns
Carries more debt than its peers — 26.01× equity
lower than 1% of its 175 Trading & Distributors peers
Heavy working capital — 486 days of cash tied up

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from SUPHA PHARMACHEM LIMITED's filed financials and exchange disclosures

What does SUPHA PHARMACHEM LIMITED do?

SUPHA PHARMACHEM LIMITED is a Commercial Services & Supplies company listed on BSE.

Does SUPHA PHARMACHEM LIMITED pay a dividend?

Not in the latest reported year — SUPHA PHARMACHEM LIMITED's dividend payout for FY25 was nil.

Is SUPHA PHARMACHEM LIMITED debt-free?

No. Debt stands at 26.01× equity, and it carries net debt of ₹1,087 Cr. That is lower than 1% of its 175 Trading & Distributors peers.

Is SUPHA PHARMACHEM LIMITED expensive compared with its peers?

On trailing P/E, SUPHA PHARMACHEM LIMITED ranks 15 of 164 in Trading & Distributors — cheaper than 91% of them, against an industry median of 13.9×. This is a position, not a valuation judgement.

How much does the SUPHA PHARMACHEM LIMITED share price move in a day?

On a typical session SUPHA PHARMACHEM LIMITED moves 2.78% — that is the median absolute close-to-close move across its last 249 trading days. Announcement days are routinely larger.

Where can I track SUPHA PHARMACHEM LIMITED's announcements?

Every NSE and BSE filing by SUPHA PHARMACHEM LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.